Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. spheropredict

SpheroPredict

A 3D advanced test for prediction of drug response in secondary liver cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 SpheroPredict project word cloud

Explore the words cloud of the SpheroPredict project. It provides you a very rough idea of what is the project "SpheroPredict" about.

spherotec    life    platform    perspectives    drug    urgent    cancers    spheroid    deathliest    alleviate    financial    chemoresistance    warrant    tumours    guidelines    survival    healthcare    body    feasibility    dealing    century    created    designed    commercialisation    published    micro    biologically    burden    first    innovative    metastasizing    patients    worldwide    spheropredict    commercial    liver    risk    tumour    solution    efficacy    quality    accurate    guideline    21st    diseases    locations    heterogeneous    cells    fail    metastatic    economic    error    trial    chemotherapy    time    patient    proven    regarding    3d    types    secondary    line    personalised    cancer    deaths    treat    medicine    lack    migrating    de    predict    era    therapy    productivity    treatment    efficient    inefficient    risked    options    toxicity    cycle    therapies    individualised    primary    drugs    entail    international    causes    death    model    treatments    installing    clear    incurred   

Project "SpheroPredict" data sheet

The following table provides information about the project.

Coordinator		 SPHEROTEC GMBH 

Organization address
address: AM KLOPFERSPITZ 19
city: MARTINSRIED
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.spherotec.com/ - www.spheromed.com - www.spheroselect.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPHEROTEC GMBH DE (MARTINSRIED) coordinator 50˙000.00

Map

 Project objective

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPHEROPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPHEROPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More